TOP HEADLINES

Editor's Corner

The top 10 FierceBiotech stories of 2014

In biotech, here are the top 10 news stories of the year so far, based on web traffic.

Price of UniQure gene therapy tops €1.1M, Fund backs RET inhibitors, Promethera bags €25M

Welcome to the latest edition of our weekly EuroBiotech Report.

FDA slaps down Bristol-Myers' marketing pitch for hep C drug daclatasvir

The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy.

Novartis cans a researcher whose cooked data led to a slew of retractions

Novartis has washed its hands of a researcher who admitted to falsifying results in a series of published papers, promising to dig into his work at the company to determine whether the pattern continued in its own labs.

UC Irvine investigators feature a new class of 'chemosensitizers'

Scientists with the UC Irvine School of Medicine and the Italian Institute of Technology have spotlighted what they call the "very first class" of acid ceramidase inhibitors that could eventually go on to help amp up the effectiveness of chemotherapies.

MORE NEWS